Pilot Study Evaluating Use of Lymphotrophic Nanoparticle-Enhanced Magnetic Resonance Imaging for Assessing Lymph Nodes in Renal Cell Cancer

Urology

Volumn 71, Issue 4, 2008, Pages 708-712

  Guimaraes, Alexander R ^a   Tabatabei, Shahin ^a   Dahl, Douglas ^a   McDougal, W Scott ^a   Weissleder, Ralph ^a   Harisinghani, Mukesh G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NANOPARTICLE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL PRACTICE; COILED BODY; CONTROLLED STUDY; FEMALE; HUMAN; KIDNEY CANCER; LYMPH NODE DISSECTION; MALE; NEPHRECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; PRIORITY JOURNAL; RADIOLOGIST; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA;

ADULT; AGED; CARCINOMA, RENAL CELL; CONTRAST MEDIA; FEMALE; HUMANS; IRON; KIDNEY NEOPLASMS; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; NEPHRECTOMY; OXIDES; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS;

EID: 41149137543     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.11.096     Document Type: Article

References (24)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
2. Pantuck A.J., Zisman A., and Belldegrun A.S. The changing natural history of renal cell carcinoma. J Urol 166 (2001) 1611-1623
3. Studer U.E., Scherz S., Scheidegger J., et al. Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases. J Urol 144 (1990) 243-245
4. Pantuck A.J., Zisman A., Dorey F., et al. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer 97 (2003) 2995-3002
5. Robson C.J., Churchill B.M., and Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol 101 (1969) 297-301
6. DeKernion J.B. Lymphadenectomy for renal cell carcinoma: therapeutic implications. Urol Clin North Am 7 (1980) 697-703
7. Freedland S.J., and Dekernion J.B. Role of lymphadenectomy for patients undergoing radical nephrectomy for renal cell carcinoma. Rev Urol 5 (2003) 191-195
8. Giberti C., Oneto F., Martorana G., et al. Radical nephrectomy for renal cell carcinoma: long-term results and prognostic factors on a series of 328 cases. Eur Urol 31 (1997) 40-48
9. Giuliani L., Martorana G., Giberti C., et al. Results of radical nephrectomy with extensive lymphadenectomy for renal cell carcinoma. J Urol 130 (1983) 664-668
10. Blom J.H., van Poppel H., Marechal J.M., et al. Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group. Eur Urol 36 (1999) 570-575
11. Novick A.C. Nephron-sparing surgery for renal cell carcinoma. Annu Rev Med 53 (2002) 393-407
12. Ferrigni R.G., and Novicki D.E. Chylous ascites complicating genitourinary oncological surgery. J Urol 134 (1985) 774-776
13. Herrlinger A., Schrott K.M., Schott G., et al. What are the benefits of extended dissection of the regional renal lymph nodes in the therapy of renal cell carcinoma. J Urol 146 (1991) 1224-1227
14. Pantuck A.J., Zisman A., Dorey F., et al. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol 169 (2003) 2076-2083
15. Schafhauser W., Ebert A., Brod J., et al. Lymph node involvement in renal cell carcinoma and survival chance by systematic lymphadenectomy. Anticancer Res 19 (1999) 1573-1578
16. Skinner D.G., Vermillion C.D., and Colvin R.B. The surgical management of renal cell carcinoma. J Urol 107 (1972) 705-710
17. Harisinghani M., and Weissleder R. Sensitive, non-invasive detection of lymph node metastases. PLOS-Med 1 (2004) e67-e71
18. Harisinghani M.G., Barentsz J., Hahn P.F., et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348 (2003) 2491-2499
19. Weissleder R., Elizaondo G., Wittenberg J., et al. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology 175 (1990) 494-498
20. Weissleder R., Elizaondo G., Wittenberg J., et al. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 175 (1990) 489-493
21. Anzai Y., Piccoli C.W., Outwater E.K., et al. Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: phase III safety and efficacy study. Radiology 228 (2003) 777-788
22. Guller U., Nitzsche E., Moch H., and Zuber M. Is positron emission tomography an accurate non-invasive alternative to sentinel lymph node biopsy in breast cancer patients?. J Natl Cancer Inst 95 (2003) 1040-1043
23. Jager G.J., Barentsz J.O., Oosterhof G.O., et al. Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional TI-weighted magnetization-prepared-rapid gradient-echo sequence. AJR Am J Roentgenol 167 (1996) 1503-1507
24. Sigal R., Vogl T., Casselman J., et al. Lymph node metastases from head and neck squamous cell carcinoma: MR imaging with ultrasmall superparamagnetic iron oxide particles (Sinerem MR)-results of a phase-III multicenter clinical trial. Eur Radiol 12 (2002) 1104-1113